Skip to Content

eSURFACE 1 and reSURFACE 2: Biological therapy improves psoriasis and CVD

As a fact, cardiovascular diseases (CVD) are highly prevalent in patients with psoriasis, and hence Professor Nehal Mehta and his team have been using this as a model to study inflammatory atherogenesis. In this MEDtalk, he presents very interesting results from the reSURFACE 1 and 2 regarding the association between psoriasis and CVD and how both conditions improve following biological therapy with tildrakizumab.

Nehal Mehta

Få tillgång till artikeln

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top